Could a targeted drug boost prostate cancer treatment?
NCT ID NCT04947254
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug niraparib to standard hormone therapy after radiation helps control high-risk prostate cancer that hasn't spread far. About 200 men will receive either hormone therapy alone or hormone therapy plus niraparib. The goal is to see if the combination delays cancer progression better than hormone therapy alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shockwaves may speed up erectile recovery after prostate cancer surgery
- Could a common blood pressure drug help fight prostate cancer?
- Can brain waves predict bladder control after prostate surgery?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- Hormone therapy plus precision radiation aims to crush prostate cancer early